this post was submitted on 01 Nov 2023
440 points (99.3% liked)

Technology

60073 readers
3765 users here now

This is a most excellent place for technology news and articles.


Our Rules


  1. Follow the lemmy.world rules.
  2. Only tech related content.
  3. Be excellent to each another!
  4. Mod approved content bots can post up to 10 articles per day.
  5. Threads asking for personal tech support may be deleted.
  6. Politics threads may be removed.
  7. No memes allowed as posts, OK to post as comments.
  8. Only approved bots from the list below, to ask if your bot can be added please contact us.
  9. Check for duplicates before posting, duplicates may be removed

Approved Bots


founded 2 years ago
MODERATORS
 

Drugmakers Are Set to Pay 23andMe Millions to Access Consumer DNA::GSK will pay the DNA testing company $20 million for non-exclusive access to genetic data.

you are viewing a single comment's thread
view the rest of the comments
[–] [email protected] 32 points 1 year ago (3 children)

if it helps accelerate the development of life saving medications

LMAO

Goldman Sachs: "Is curing patients a sustainable business model?"

Not if Wall Street has anything to do with it!

[–] eager_eagle 9 points 1 year ago

We may and should point to all questionably bad practices of these drug companies, but I think humanity is still far better off with their research advancements than without them. So I'm all for using my data for that purpose like 23andMe is doing. Now insurance companies and lobbyists - these can go to hell.

[–] [email protected] 3 points 1 year ago

If you can keep someone from dying by being dependent on only your medication, you've created a customer for life rather than one who died and didn't give you all their money to live another day.

[–] [email protected] 3 points 1 year ago* (last edited 1 year ago)

The name of the report is horrific, but a little misleading with just the title. It's specifically a report about gene therapies, which are obviously still happening. Just look at spinal muscular atrophy, Duchene muscular dystrophy, sickle cell anemia about to be approved, and many others already approved or well on their way.

The main points of the report are a little more benign than the title of the report would suggest and are mostly making suggestions on how to keep a biotech company that is focused on developing cures for rare diseases solvent and running. Their main suggestions were to have a mix of both common and rare diseases, prioritizing diseases with high morbidity (like spinal muscular atrophy), and to keep a constant pipeline of new cures coming out for more rare diseases.

Don't get me wrong I have many issues with big pharma, but the way that analyst's report title gets used is very misleading.